

ZIOPHARM ONCOLOGY INC  
Form 8-K  
May 21, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 21, 2010

---

ZIOPHARM Oncology, Inc.  
(Exact Name of Registrant as Specified in Charter)

|   |  |  |
|---|--|--|
| Delaware<br>(State or Other Jurisdiction<br>of Incorporation) | 001-33038<br>(Commission File<br>Number) | 84-1475672<br>(IRS Employer<br>Identification No.) |
|---|--|--|

|   |                     |
|---|---------------------|
| 1180 Avenue of the Americas<br>19th Floor<br>New York, NY<br>(Address of Principal Executive Offices) | 10036<br>(Zip Code) |
|---|---------------------|

(646) 214-0700  
(Registrant's telephone number, including area code)

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

---

Item 8.01 Other Events

On May 21, 2010, the Company issued a press release announcing that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author on the abstract for the Company's palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7, 2010.

A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report of Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | Description                                     |
|-------------|---|
| 99.1        | Press Release of the Company dated May 21, 2010 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

Date: May 21, 2010

By: /s/ Richard Bagley  
Name: Richard Bagley  
Title: President, Chief Operating Officer  
and Chief Financial Officer

INDEX OF EXHIBITS

| Exhibit No. | Description                                     |
|-------------|---|
| 99.1        | Press Release of the Company dated May 21, 2010 |

4

---